Abstract
The synuclein family, consisting of α-, β-, and γ-synuclein, is primarily expressed in neurons. Mutations of α- and β-synuclein have been linked to Parkinson's disease and dementia with Lewy bodies, respectively. Recent studies have shown that synucleins are upregulated in various tumors, including breast, ovarian, meningioma, and melanoma, and high synuclein expression is associated with poor prognosis and drug resistance. We report a novel rearrangement of β-synuclein in a pediatric T-cell acute lymphoblastic leukemia (T-ALL) case, where β-synuclein (SNCB) is fused in-frame with ETS variant transcription factor 6 (ETV6), a gene frequently rearranged in acute leukemia including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL), and T-ALL. An additional case of β-synuclein rearrangement was identified in a squamous cell carcinoma of the lung through analysis of the public TCGA database. Both rearrangements involve the C-terminal of β-synuclein. Since β-synuclein shares extensive amino acid similarities with α-synuclein and α-synuclein binds to 14-3-3, an important regulator of apoptosis, the rearranged β-synuclein may contribute to tumorigenesis by deregulating apoptosis. In addition, overexpression of synucleins has been shown to increase cell proliferation, suggesting that the rearranged β-synuclein may also deregulate the cell cycle.
Introduction
The synuclein family of proteins (α, β, and γ) is traditionally associated with neurodegenerative disorders such as Parkinson's disease and dementia with Lewy bodies. However, emerging research indicates that these proteins are also upregulated in various malignancies, where they often correlate with poor prognosis and drug resistance. Despite this growing link, structural variations—specifically gene fusions involving the β-synuclein gene (SNCB)—have not been previously reported in cancer. This study documents the first known cases of SNCB rearrangements in human malignancies, exploring a novel oncogenic role for a protein typically associated with brain pathology.
Materials and Methods
The researchers utilized a combination of clinical diagnostics and bioinformatics to investigate potential SNCB rearrangements. For the primary clinical case, a 5-year-old patient with pediatric T-cell acute lymphoblastic leukemia (T-ALL), standard karyotyping and Fluorescence in situ hybridization (FISH) were employed to identify chromosomal translocations. Targeted RNA next-generation sequencing (NGS) using a panel of 75 hematology-related genes was then used to identify the specific genes involved. Findings were validated via RT-PCR and Sanger sequencing.
To determine the prevalence of such rearrangements beyond this single case, the authors computationally mined public cancer genomes from The Cancer Genome Atlas (TCGA). They queried 10,565 cancer genomes, specifically focusing on a cohort of 423 lung squamous cell carcinoma cases to identify additional SNCB fusions.
Results
Identification of ETV6::SNCB in Pediatric T-ALL
In the pediatric T-ALL patient, the team discovered two novel, in-frame fusion transcripts: ETV6::SNCB and a rare three-gene read-through product, ETV6::SNCB::GPRIN1. This discovery marks SNCB as the 39th identified fusion partner for ETV6, a gene known for its promiscuity in leukemias.
Clinical tracking of these transcripts proved highly effective for monitoring Minimal Residual Disease (MRD). Following standard chemotherapy, the patient achieved remission; RT-PCR tracking showed that the ETV6::SNCB transcript disappeared by day 19, followed by the clearance of ETV6::SNCB::GPRIN1 by day 46, mirroring the patient's clinical recovery.
Cross-Cancer Relevance
Database mining revealed that SNCB rearrangements are not limited to hematological malignancies. A distinct LDLRAD3::SNCB fusion was identified in a 46-year-old patient with lung squamous cell carcinoma (TCGA-85-A50M-01A). Notably, both the leukemia and lung cancer fusions preserve the C-terminal acidic region of β-synuclein, suggesting a conserved functional mechanism across different cancer types.
Discussion
The structural consistency of these fusions, particularly the preservation of the C-terminal domain, points toward a specific oncogenic mechanism. The C-terminal of synucleins is known to bind to 14-3-3 proteins, which are critical regulators of apoptosis (programmed cell death). The authors hypothesize that highly expressed SNCB fusion proteins may sequester 14-3-3, thereby blocking apoptotic signaling and allowing tumor cells to proliferate unchecked.
While these findings are significant, the proposed mechanism remains theoretical and requires direct experimental validation. Future work involving functional in vitro and in vivo studies is necessary to confirm how these chimeric proteins affect the cell cycle and apoptosis. Understanding these pathways could provide deeper insights into both tumor biology and the physiological role of β-synuclein in neurodegeneration.
Summary updated